mr 2034 has been researched along with naloxazone in 2 studies
| Studies (mr 2034) | Trials (mr 2034) | Recent Studies (post-2010) (mr 2034) | Studies (naloxazone) | Trials (naloxazone) | Recent Studies (post-2010) (naloxazone) |
|---|---|---|---|---|---|
| 48 | 0 | 0 | 41 | 1 | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ensinger, HA | 2 |
2 other study(ies) available for mr 2034 and naloxazone
| Article | Year |
|---|---|
Differentiating aspects of opioid receptor binding by [3H](-) (1R,5R,9R,2''S)-5,9-dimethyl-2-tetrahydrofurfuryl-2'-hydroxy-6,7- benzomorphan hydrochloride ([3H]Mr 2034), a drug preferentially acting on kappa-receptors.
Topics: Animals; Benzomorphans; Binding, Competitive; Cyclazocine; Dihydromorphine; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Ethylketocyclazocine; In Vitro Techniques; Kinetics; Male; Morphinans; Naloxone; Rats; Receptors, Opioid; Receptors, Opioid, kappa | 1985 |
[3H]Mr 2034 labels a high affinity opioid kappa-receptor not accessible to naloxazone.
Topics: Animals; Benzomorphans; Binding, Competitive; Brain; Cyclazocine; Ethylketocyclazocine; In Vitro Techniques; Kinetics; Morphinans; Naloxone; Rats; Receptors, Opioid; Receptors, Opioid, kappa | 1983 |